CSPG4 and neoplasm: For this reason, our approach was focused on combining a low-affinity CSPG4-targeting CAR, which by itself only showed weak anti-tumor cytotoxicity, with an anti-CD20 chimeric co-stimulatory co-receptor (CCR).